Quick Update for Moderna (MRNA) Investors

Shares of Health Care sector company Moderna moved -0.8% today, and are now trading at a price of $79.95. The large-cap stock's daily volume was 3,335,217 compared to its average volume of 4,105,133. The S&P 500 index returned a 1.0% performance.

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. The company is based in Cambridge and has 3,900 full time employees. Its market capitalization is $30,483,654,656.

19 analysts are following Moderna and have set target prices ranging from $52.0 to $300.0 per share. On average, they have given the company a rating of hold. At today's prices, MRNA is trading -40.41% away from its average analyst target price of $134.16 per share.

Over the last year, MRNA shares have gone down by -57.0%, which represents a difference of -74.0% when compared to the S&P 500. The stock's 52 week high is $217.25 per share and its 52 week low is $62.55. Although Moderna's average free cash flow over the last 6 years has been $2.72 Billion, they have been decreasing at an average rate of -35.1%. For this reason, investors may continue to shun the stock.

Date Reported Cash Flow from Operations ($ k) Capital expenditures ($ k) Free Cash Flow ($ k) YoY Growth (%)
2023 -2,078,000 579,000 -2,657,000 -158.0
2022 4,981,000 400,000 4,581,000 -65.65
2021 13,620,000 284,000 13,336,000 580.76
2020 2,027,000 68,000 1,959,000 498.98
2019 -459,000 32,000 -491,000 -12.45
2018 -330,865 105,766 -436,631
The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.